August 2021 - Page 3 of 3 - CanadianCannabisWire

TuesdayAug 03, 2021 9:30 am

InMed Pharmaceuticals Inc. (NASDAQ: INM) Is ‘One to Watch’

InMed has a world class leadership team with a successful track record of drug development and commercialization The company recently announced closing of a $12 million private placement InMed has a solid and expanding intellectual property portfolio with multiple patents filed The company recently signed an LOI to acquire rare cannabinoids manufacturer BayMedica InMed retains all commercial rights to its IntegraSyn manufacturing system InMed has filed clinical trial applications in several countries as part of a Phase 2 clinical trial of INM-755 (cannabinol) cream in epidermolysis bullosa The consumer market for cannabinoid-based pharmaceuticals in the United States is forecast to…

TuesdayAug 03, 2021 9:00 am

Chalice Brands Ltd. (CSE: CHAL) (OTCQB: CHALF) Names New Executive, Retains PR Firm

CHALF appoints retail veteran Ginger Mollo as chief integration officer, Fifth & Root GM Mollo will oversee the positioning, expansion of the Fifth & Root Brand within the health and wellness beauty market as well as integration into Chalice brands Chalice has engaged MP-IMC to heighten profile of Fifth & Root in Chalice Brands product portfolio Chalice Brands (CSE: CHAL) (OTCQB: CHALF), a premier consumer-driven cannabis company specializing in retail, production, processing, wholesale, and distribution, has appointed retail veteran Ginger Mollo as chief integration officer for the company. In addition, Mollo will also serve as general manager of Fifth &…

MondayAug 02, 2021 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Steadily Achieving Its Operational and Business Plan Objectives

Lexaria just completed dosing for its second human clinical study, HYPER-H21-2 The study sought to understand the human response to Lexaria’s DehydraTECH 2.0-enabled CBD The company also announced that its DehydraTECH-enabled consumer products are available for purchase in over 7,000 stores across the United States Lexaria also expanded its intellectual property portfolio with the allowance of its second patent in Japan It also received US$3,817,643 from warrant exercises, proceeds from which will be used to advance the company’s research and development program and for its general corporate purposes Lexaria Bioscience (NASDAQ: LEXX) has been making incredible strides in 2021 as…